Further in-depth study of the physiological and pathological effects of the apelin/APJ system on ischemic stroke and the potential mechanisms will help to guide clinical prevention of and intervention in ischemic stroke and develop a series of drugs targeting different subtypes and phases of the disease, providing good news for patients, which will reduce family and social burdens. This evidence concerns the gene APLNR and ischemic stroke.